Amyris, Inc. (NASDAQ:AMRS – Get Rating) CAO Anthony Hughes sold 6,305 shares of the company in a trade dated Thursday, June 2. The stock was sold at an average price of $2.34, for a total transaction of $14,753.70. Following completion of the transaction, the chief accounting officer now owns 106,612 shares of the company, valued at $249,472.08. The transaction was disclosed in a document filed with the SEC, accessible via this hyperlink.

AMRS shares traded down $0.12 during Friday trading hours, hitting $2.38. The stock recorded a trading volume of 4,186,317 shares, compared to an average volume of 6,133,438 shares. The company has a debt ratio of 1.26, a current ratio of 1.77 and a quick ratio of 1.46. Amyris, Inc. has a 12-month low of $1.47 and a 12-month high of $17.42. The company has a 50-day simple moving average of $3.40 and a 200-day simple moving average of $4.47. The company has a market capitalization of $760.92 million, a PE ratio of -1.93 and a beta of 1.66.

Amyris (NASDAQ:AMRS – Get Rating) last released quarterly earnings data on Tuesday, May 10. The biotech company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimate of ($0.24) by ($0.13). The company posted revenue of $57.71 million for the quarter, versus analyst estimates of $65.45 million. In the same quarter a year earlier, the company posted ($1.08) earnings per share. The company’s revenue for the quarter was down 67.4% year over year. On average, stock analysts expect Amyris, Inc. to post -0.85 earnings per share for the current year.

A number of research analysts have recently released reports on AMRS stocks. StockNews.com began covering Amyris shares in a research report on Thursday, March 31. They issued a “sell” rating on the stock. Zacks Investment Research downgraded Amyris shares from a “hold” rating to a “sell” rating in a Monday, May 16 research report. Finally, Piper Sandler began covering Amyris shares in a research report on Wednesday, May 25. They issued a “neutral” rating and a price target of $2.50 on the stock. Two analysts have assigned the stock a sell rating, one has assigned a hold rating and three have assigned the company’s stock a buy rating. Based on data from MarketBeat, Amyris currently has an average rating of “Hold” and a consensus price target of $16.25.

Institutional investors have recently increased or reduced their stake in the company. Qube Research & Technologies Ltd acquired a new position in Amyris during Q4 worth approximately $152,000. Geode Capital Management LLC increased its stake in Amyris by 2.6% in the third quarter. Geode Capital Management LLC now owns 3,333,551 shares of the biotech company valued at $45,769,000 after purchasing an additional 83,539 shares during the period. Gordian Capital Singapore Pte Ltd acquired a new position in Amyris during Q4 valued at approximately $26,000. Capital Performance Advisors LLP acquired a new position in Amyris during the 4th quarter worth approximately $41,000. Finally, the Swiss National Bank increased its stake in Amyris by 1.8% during the 4th quarter. The Swiss National Bank now owns 360,600 shares of the biotech company valued at $1,951,000 after buying an additional 6,400 shares during the period. 49.43% of the shares are currently held by hedge funds and other institutional investors.

Amyris Company Profile (Get a rating)

Amyris, Inc, a synthetic biotechnology company, operates in the clean health and beauty, flavor and fragrance markets in Europe, North America, Asia and South America. The Company manufactures and sells clean beauty, personal care, health and wellness consumer products and ingredients for the flavor and fragrance, nutrition, food and beverage, and beverage end markets. clean beauty and personal care.

Further reading

Insider buying and selling by quarter for Amyris (NASDAQ:AMRS)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Amyris right now?

Before you consider Amyris, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Amyris wasn’t on the list.

While Amyris currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here